|
|
|
|
|
|
|
|
|
|
|
| |
|
| Portfolio |
|
AVF I |
AVC |
FITE/FITE II |
DecImmune Therapeutics, Inc. Boston, MA, USA |
Cellzome AG
Heidelberg, Germany |
Alba Therapeutics Baltimore, MD, USA |
| EpiZyme, Inc. Cambridge, MA, USA
|
Evolva
SA Allschwill, Switzerland |
FASgen
Baltimore, MD, USA |
|
F2G, Ltd. Manchester, UK
|
CoMentis, Inc.
So. San Francisco, CA, USA |
Linden Bioscience
Woburn, MA, USA |
|
Fate Therapeutics, Inc. San Diego, CA, USA
|
Plexxikon, Inc.
Berkely, CA, USA |
Neuronautics, Inc.
Highland Park, IL, USA |
|
Inimex Pharmaceuticals, Inc. Burnaby, BC, Canada
|
|
PhysioGenix, Inc.
Wauwatosa, WI, USA |
|
Lectus Therapeutics Ltd.
Cambridge, UK
|
|
Renovar Incorporated
Madison, WI, USA |
|
Nereus Pharmaceuticals, Inc.
San Diego, CA, USA
|
|
Revivicor, Inc.
Blacksburg, VA, USA |
Viamet Pharmaceuticals, Inc.
Morrisville, NC, USA |
|
|
Portfolio Exits |
|
AVF I |
AVC |
FITE/FITE II |
Intradigm Corporation
Palo Alto, CA, USA |
AkaRx, Inc. Paramus, NJ, USA |
Adhelex Technologies Ottawa, Canada |
|
EPIX Pharmaceuticals
Cambridge, MA, USA |
Ception Therapeutics
Rockville, MD, USA |
|
Memory Pharmaceuticals
Montvale, NJ, USA |
Cytomyx Holdings PLC
Cambridge, UK |
|
|
Prolysis Limited
Oxfordshire, UK |
|
|
|
|